Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive versus standard uric acid–lowering therapy with topiroxostat in CKD patients
jRCTs051180146Completed
- Sponsor
- Fuji Yakuhin
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of topiroxostat in chronic kidney disease (CKD) and hyperuricemia (2 arms), sponsored by Fuji Yakuhin. Primary endpoint: Change in urinary albumin-to-creatinine ratio (log-transformed). Started Nov 2017; status: completed.
02
Drugs
topiroxostat
03
Conditions
chronic kidney disease (CKD)hyperuricemia
Beyond the preview
Go deeper on jRCTs051180146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180146.